247 related articles for article (PubMed ID: 35598768)
1. Application of physiologically based absorption and pharmacokinetic modeling in the development process of oral modified release generic products.
Subhani S; Kim C; Muniz P; Rodriguez M; van Os S; Suarez E; Cristofoletti R; Schmidt S; Vozmediano V
Eur J Pharm Biopharm; 2022 Jul; 176():87-94. PubMed ID: 35598768
[TBL] [Abstract][Full Text] [Related]
2. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
[TBL] [Abstract][Full Text] [Related]
3. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
Loisios-Konstantinidis I; Dressman J
Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
[TBL] [Abstract][Full Text] [Related]
5. Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products.
Jadhav H; Augustijns P; Tannergren C
Mol Pharm; 2023 Dec; 20(12):6272-6288. PubMed ID: 37902586
[TBL] [Abstract][Full Text] [Related]
6. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based biopharmaceutics modeling of regional and colon absorption in humans.
Tannergren C; Jadhav H; Eckernäs E; Fagerberg J; Augustijns P; Sjögren E
Eur J Pharm Biopharm; 2023 May; 186():144-159. PubMed ID: 37028605
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.
Eckernäs E; Tannergren C
Mol Pharm; 2021 Apr; 18(4):1699-1710. PubMed ID: 33720733
[TBL] [Abstract][Full Text] [Related]
9. Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.
Tistaert C; Heimbach T; Xia B; Parrott N; Samant TS; Kesisoglou F
J Pharm Sci; 2019 Jan; 108(1):592-602. PubMed ID: 29906472
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic Modeling of In Vitro Biopharmaceutic Data for a Weak Acid Drug: A Pathway Towards Deriving Fundamental Parameters for Physiologically Based Biopharmaceutic Modeling.
Kowthavarapu VK; Charbe NB; Gupta C; Iakovleva T; Stillhart C; Parrott NJ; Schmidt S; Cristofoletti R
AAPS J; 2024 Apr; 26(3):44. PubMed ID: 38575716
[TBL] [Abstract][Full Text] [Related]
11. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
[TBL] [Abstract][Full Text] [Related]
12. Progressive tools and critical strategies for development of best fit PBPK model aiming better in vitro-in vivo correlation.
Golhar A; Pillai M; Dhakne P; Rajput N; Jadav T; Sengupta P
Int J Pharm; 2023 Aug; 643():123267. PubMed ID: 37488057
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based Pharmacokinetic Models under the Prism of the Finite Absorption Time Concept.
Wu D; Tsekouras AA; Macheras P; Kesisoglou F
Pharm Res; 2023 Feb; 40(2):419-429. PubMed ID: 36050545
[TBL] [Abstract][Full Text] [Related]
14. PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.
Stillhart C; Pepin X; Tistaert C; Good D; Van Den Bergh A; Parrott N; Kesisoglou F
AAPS J; 2019 Jan; 21(2):19. PubMed ID: 30673891
[TBL] [Abstract][Full Text] [Related]
15. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.
Margolskee A; Darwich AS; Pepin X; Aarons L; Galetin A; Rostami-Hodjegan A; Carlert S; Hammarberg M; Hilgendorf C; Johansson P; Karlsson E; Murphy D; Tannergren C; Thörn H; Yasin M; Mazuir F; Nicolas O; Ramusovic S; Xu C; Pathak SM; Korjamo T; Laru J; Malkki J; Pappinen S; Tuunainen J; Dressman J; Hansmann S; Kostewicz E; He H; Heimbach T; Wu F; Hoft C; Laplanche L; Pang Y; Bolger MB; Huehn E; Lukacova V; Mullin JM; Szeto KX; Costales C; Lin J; McAllister M; Modi S; Rotter C; Varma M; Wong M; Mitra A; Bevernage J; Biewenga J; Van Peer A; Lloyd R; Shardlow C; Langguth P; Mishenzon I; Nguyen MA; Brown J; Lennernäs H; Abrahamsson B
Eur J Pharm Sci; 2017 Jan; 96():610-625. PubMed ID: 27816631
[TBL] [Abstract][Full Text] [Related]
16. Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs.
Melillo N; Aarons L; Magni P; Darwich AS
J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):27-42. PubMed ID: 30552544
[TBL] [Abstract][Full Text] [Related]
17. Investigating the Critical Variables of Azithromycin Oral Absorption Using In Vitro Tests and PBPK Modeling.
Guimarães M; Somville P; Vertzoni M; Fotaki N
J Pharm Sci; 2021 Dec; 110(12):3874-3888. PubMed ID: 34530004
[TBL] [Abstract][Full Text] [Related]
18. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Absorption Modeling to Impact Biopharmaceutics and Formulation Strategies in Drug Development-Industry Case Studies.
Kesisoglou F; Chung J; van Asperen J; Heimbach T
J Pharm Sci; 2016 Sep; 105(9):2723-2734. PubMed ID: 26886317
[TBL] [Abstract][Full Text] [Related]
20. Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration.
O'Dwyer PJ; Box KJ; Dressman J; Griffin BT; Henze LJ; Litou C; Pentafragka C; Statelova M; Vertzoni M; Reppas C
J Pharm Pharmacol; 2021 Mar; 73(4):437-446. PubMed ID: 33793836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]